ANALYSIS ON A NOVEL DRUG DELIVERY SYSTEMS IN ANESTHESIA

[1]Dr. Aarti Chouhan
Assistant Professor of Botany,
Govt Maharani Laxmi Bai Girls PG College, Indore MP, India
Affiliation: Devi Ahilya Vishwavidhyalaya DAVV, Indore MP
Email: aarti8090@gmail.com

[2]Dr.Gavhane Vrushali Somanath
Assistant Professor
R.B.Attal Arts, Science and Commerce College, Georai Dist. Beed
drvrushaligavhane@gmail.com

[3]Dr Yogesh Jorapur,
Assistant Professor,
Department of Chemistry, Pratibha College of Commerce and Computer Studies,
Chinchwad, Pune , dryogeshrjorapur@gmail.com

[4]Dr. Satish B. Jadhav
Assistant Professor,
R. B. Attal Art's, Science and Commerce College, Georai, Dist. - Beed, Maharashtra
Email id - orgchem.jadhav@gmail.com

Abstract

Recent years have seen a significant shift in drug delivery technologies. Modern efforts are concentrated on minimising risks while maximising benefits. Launching additional compounds is expensive, so instead, the industry is focusing on making the ones it already has more effective. Therefore, new infusion methods such as closed loop infusion, target controlled infusion, and controlled release have emerged. It is possible that applying pharmacokinetic principles, rather than quantitatively determining drug dose, might increase patient safety and help to keep drug levels stable in the body. Applying computers to a well-designed operating system can only boost its effectiveness. Most of these once-research-only technologies are now routinely used in clinical settings. Because of this, it is essential for today's clinicians to become conversant with these tools. Here, we've focused on the newest drug delivery methods that can be used in anesthesiology.

Introduction

It takes a lot of time and money to create a brand new medication molecule. Various strategies, such as tailoring medication therapy, adjusting doses, and keeping close tabs on therapeutic drug effects, have been tried in an effort to increase the safety and effectiveness ratio of "old" pharmaceuticals. Other extremely appealing strategies have been extensively researched, such as controlled drug delivery, delayed drug delivery, and targeted medication delivery. It's worth noting that researchers from India have contributed significantly to and been published in a wide variety of works from the United States and Europe. [1–3] Pharmacokinetic and pharmacodynamic principles governing the action and disposition of

powerful opioid analgesics, inhalation anaesthetic drugs, sedative/hypnotics, and muscle relaxants have been better understood thanks to numerous animal and human studies. Evidence from these investigations points to the possibility that the skin and buccal and nasal mucosa can be used as additional entry points for analgesic and anaesthetic drugs. Similar progress with other substances has resulted in a variety of new tools, ideas, and approaches that make up what is now known as controlled-release technology (CRT). Controlled-release technologies (CRTs) include, but are not limited to, programmable implanted drug-delivery systems, transdermal and transmucosal controlled-release delivery systems, ml6 nasal and buccal aerosol sprays, drug-impregnated lozenges, encapsulated cells, oral soft gels, and iontophoretic devices to administer drugs through skin. Numerous motivating forces are pushing researchers to create innovative tools, strategies, and methods. Although conventional drug delivery methods are used frequently, there are various drawbacks to them that these alternatives may address. In the same vein, the advances may look promising when compared to the expense of creating a whole new medicine. Since the late 1950s, the introduction of novel chemical entities has slowed significantly due to factors such as rising R&D costs, other investment options for drug corporations, a drop in the number of firms performing pharmaceutical research, and the loss of effective patent life. Bringing a novel medicine through research, clinical testing, development, and regulatory approval is presently projected to take a decade and cost well over $ 120 million. By the year 2000, it's possible that 40% of all pharmaceuticals sold in the United States would use novel drug delivery technologies. [4–6].

Pharmacokinetic Closed-Loop Systems in Anesthesia

The concentration of various medications that have expired can be monitored in real time. This can be done clinically with the spectrometric gas analyzers used in most anaesthesia monitors for inhaled anaesthetics such desflurane, sevoflurane, and isoflurane. A closed-loop device can be used to regulate the inhaled anaesthetic concentration to achieve a desired inspired or end-tidal level. A number of experimental control systems [5, 6] have been created over the past few decades. Recent years have also seen the introduction of the first commercially available closed-circuit anaesthetic ventilator (Zeus®, Dräger Medical, Lübeck, Germany). Using closed-loop technology, this device can regulate the flow of new gas while simultaneously aiming for certain end-tidal concentrations of inhaled anaesthetics [7].

Propofol concentration in exhaled air has been measured experimentally using proton transfer mass spectrometry and headspace solid-phase microextraction coupled with gas chromatography-mass spectrometry (HS-SPME-GC-MS) [8, 9] or ion mobility spectrometry coupled to a multicapillary column for pre-separation (MCC-IMS). Gas chromatography mass spectrometry was utilised by Grossherr et al. [9] to determine the amount of propofol in exhaled air. No closed-loop systems have been established with the concentration of propofol in the exhaled air as the regulating variable, and their use is currently considered experimental.

Pharmacokinetic-Dynamic Closed-Loop Systems

The Controlled Variable

The precision of closed-loop drug delivery is highly dependent on the stability and dependability of the variable under control. The physiological effects of drugs can be evaluated in a variety of ways. Physiological parameters that can be monitored and controlled include heart rate, breathing rate, blood pressure, and neuromuscular blockade. The response from the carefully administered cardiovascular medications, anaesthetics, and muscular blocking agents has been steered by several research groups using direct measures. Some of these devices, such the IVAC Titrator (Carefusion, San Diego, CA, USA), which adjusted the amount of nitroprusside administered by monitoring the patient's blood pressure, were once on the market but have since been taken off the market. However, these direct measurements cannot be used to monitor the hypnotic aspect of anaesthesia or the equilibrium between nociception and antinociception; instead, surrogate measures are necessary. A full correlation with all degrees of pharmacological action may be missing, thus they must be regarded with caution.

In order to study the effects of hypnotic drugs, researchers have examined a number of surrogate metrics. Electro-encephalogram (EEG) recordings, both spontaneous and evoked, have been shown to be reliable measures of the effects of hypnotic drugs on the brain, making them promising candidates for use in a closed-loop study of hypnosis with controlled variables. EEG derivatives such as spectral edge frequency (SEF) and median frequency (MEF) were used in early closed-loop systems [10]. Recently, numerous studies have used the bispectral index (BIS, Covidien, Boulder, CO, USA) as a randomised control. Using multivariate statistical analysis, BIS combines many aspects of the electrical activity of the brain to provide a more precise reading. These aspects include higher-order spectra and phase correlations between spectra. Two spectral entropy measures based on the irregularity in the EEG have recently been employed to quantify the effect of hypnotic drugs during closed-loop administration [11-13], joining BIS, State and Response Entropy (M-entropy, GE Healthcare, Helsinki, Finland). A controlled variable for closed-loop propofol administration has been investigated by one study group, and that variable is the mid-latency auditory evoked potential (MLAEP) [14, 15]. The time lag introduced by the surrogate measure increases the controller's complexity, which is one of its main drawbacks. All existing indices respond to shifts in anaesthetic intensity with varying latencies. Using a simulated EEG signal, Pilge and colleagues examined the delays in three widely available computerised EEG systems and reported delays ranging from 14 seconds to 155 seconds [16].

Problems with closed-loop analgesic administration stem from the fact that maintaining a healthy nociception/antinociception balance is not easy. Although Liu et al. [13•] employed EEG to co-administer propofol and opioids, there is still no true "analgesia index" in closed-loop. Mathews and colleagues [17] found that remifentanil could be delivered using an algorithm that maintains the difference between RE and SE between the upper and lower boundary condition as a measure of frontal electromyographic (FEMG) activity, but this has not been implemented in a closed-loop system. The same scientists have recently discovered that the Composite Variability Index (CVI), based on the variability in BIS and FEMG

activity, can be useful to predict movement during anaesthesia, which can be reduced by providing analgesics [18].

Liposomal and Targeted Drug Delivery System

Improved efficacy and/or decreased toxicity for anticancer drugs are theoretically possible thanks to drug delivery methods. Liposomes and other long circulating macromolecular carriers can take advantage of the 'increased permeability and retention' effect to preferentially extravasate from tumour arteries. Liposomal anthracyclines, such as liposomal daunorubicin and pegylated liposomal doxorubicin, have significantly longer circulation and have achieved highly effective drug encapsulation, resulting in considerable anticancer efficacy with reduced cardiotoxicity. Both alone and in combination with other chemotherapeutics, pegylated liposomal doxorubucin has demonstrated significant success in the treatment of breast cancer. More liposome constructions are being made to facilitate the transport of various medications. Immunoliposomes and other ligand-directed structures provide a combination of biological components capable of tumour recognition with delivery technologies, and so represent the next generation of delivery systems that will incorporate genuine molecular targeting. The stable formulation, better pharmacokinetics, and partial "passive" or "physiological" targeting to tumour tissue provided by currently approved liposomal drug delivery technologies have already been reviewed in [5]. However, these transporters are not designed to kill tumour cells [6, 7]. Liposomes can avoid interacting with tumour cells because of design adjustments that shield them from interactions with plasma proteins and cell membranes, and that set them apart from reactive carriers like cationic liposomes. When liposomes are extravasated into tumour tissue, they do not disperse across the tumour microenvironment but rather remain within the tumour stroma as a drug-loaded depot. Eventually, the liposomes will be broken down by enzymes and/or phagocytized, releasing the medication for continued diffusion to the tumour cells. Direct molecular targeting of cancer cells via antibody-mediated or other ligand-mediated interactions is a key characteristic of the next generation of drug carriers now in development.

An approach to molecularly targeted medication delivery, immunoliposomes involve the conjugation of mAb fragments to liposomes.

Long-circulating liposomes conjugated to Fab' or scFv fragments are the basis of anti-HER2 immunoliposomes[9]. Effective intracellular delivery of encapsulated medicines was demonstrated in preclinical trials using anti-HER2 immunoliposomes, which adhered to and were internalised by HER2-overexpressing cells. By far outperforming any other treatment tried, anti-HER2 immunoliposomes loaded with doxorubicin showed strong and selective anticancer effect against HER2-overexpressing malignancies (free doxorubicin, liposomal doxorubicin, free mAb [trastuzumab], and combinations of trastuzumab plus doxorubicin or liposomal doxorubicin). Clinical trials using anti-HER2 immunoliposomes are currently in the scaling up phase [10]. [9,11]

When compared to previous antibody-based approaches, the immunoliposome technique has several potential benefits. The cardiotoxicity of trastuzumab plus doxorubicin may be avoided through the use of anti-HER2 immunoliposome delivery of doxorubicin. scFv can be

used to create an anti-HER2 immunoliposome that, in contrast to trastuzumab, does not inhibit proliferation, cannot induce antibody-dependent cellular cytotoxicity, and needs a certain amount of HER2 expression before it can be delivered. The exponentially larger capacity of drug-loaded liposomes is utilised by immunoliposomes, as opposed to drug immunoconjugates, which consist of a modest number of medications (usually 10 drugs per mAb) directly attached via linkers to chosen residues on the mAb (up to 104 drugs per liposome). Despite their repeated use, immunoliposomes do not appear to provoke an immune response. [12] Polymer systems are being developed with antibody-based targeting. Both liposomes and polymers are being studied in conjunction with ligand-based targeting methods that employ growth factors, hormones, vitamins (e.g., folate), peptides, or other particular ligands. Multilamellar liposomes (MLVs), small unilamellar vesicles (SUVs), and large unilamellar vesicles (LUVs) are all types of liposomes that differ only in the number of bilayers they contain (LUVs). The diameters of these particles are between 0.025 and 10. The method of manufacture and composition determines the size and shape of the liposomes. Drugs, vaccinations, and gene therapy for treating a wide range of diseases are all transported inside of liposomes. [13]

Conclusion

There are a large number of research facilities in India dedicated to improving medication delivery systems. The release profile and, in certain circumstances, the pharmacokinetics and, less frequently, the efficacy of these are being studied in the lab. Few clinical investigations and patient outcomes with the DDS have been reported. Research on the pharmacokinetics and pharmacodynamics of DDS must include input from pharmacologists if the products are to reach their relevant endpoint, namely clinical use.

References

1. Buvanendran A, Kroin JS. Useful adjuvants for postoperative pain management. *Best Pract Res Clin Anaesthesiol.* 2007;21:31–49. [PubMed] [Google Scholar]

2. Rosen H, Abribat T. The rise and rise of drug delivery. *Nat Rev Drug Discov.* 2005;4:381–5. [PubMed] [Google Scholar]

3. Kshirsagar NA. Drug delivery systems. *Indian J Pharmacol.* 2000;32:S54–61. [Google Scholar]

4. Dhote V, Bhatnagar P, Mishra PK, Mahajan SC, Mishra DK. Iontophoresis: A potential emergence of a transdermal drug delivery system. *Sci Pharm.* 2012;80:1–28. [PMC free article] [PubMed] [Google Scholar]

5. Talegaonkar S, Mishra PR. Intranasal delivery: An approach to bypass the blood brain barrier. *Indian J Pharmacol.* 2004;36:140–7. [Google Scholar]

6. Sakane T, Akizuki M, Yoshida M, Yamashita S, Nadai T, Hashida M, et al. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. *J Pharm Pharmacol.* 1991;43:449–51. [PubMed] [Google Scholar]

7. Westin UE, Boström E, Gråsjö J, Hammarlund-Udenaes M, Björk E. Direct nose-to-brain transfer of morphine after nasal administration to rats. *Pharm Res.* 2006;23:565–72. [PubMed] [Google Scholar]

8. Illum L. Nasal drug delivery: New developments and strategies. *Drug Discov Today.* 2002;7:1184–9. [PubMed] [Google Scholar]

9. Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, Tian XQ. Current approaches to enhance CNS delivery of drugs across the brain barriers. *Int J Nanomedicine.* 2014;9:2241–57. [PMC free article] [PubMed] [Google Scholar]

10. Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. *J Control Release.* 2014;190:15–28. [PMC free article] [PubMed] [Google Scholar]

11. Yadav N, Lohani A. A dry powder inhaler: A review. *Indo Glob J Pharm Sci.* 2013;3:142–55. [Google Scholar]

12. Shaikh S, Nazim S, Khan T, Shaikh A, Zameeruddin M, Quazi A. Recent advances in pulmonary drug delivery system: A review. *Int J Appl Pharm.* 2010;2:27–31. [Google Scholar]

13. Mather LE, Woodhouse A, Ward ME, Farr SJ, Rubsamen RA, Eltherington LG. Pulmonary administration of aerosolised fentanyl: Pharmacokinetic analysis of systemic delivery. *Br J Clin Pharmacol.* 1998;46:37–43. [PMC free article] [PubMed] [Google Scholar]

14. Worsley MH, MacLeod AD, Brodie MJ, Asbury AJ, Clark C. Inhaled fentanyl as a method of analgesia. *Anaesthesia.* 1990;45:449–51. [PubMed] [Google Scholar]

15. Higgins MJ, Asbury AJ, Brodie MJ. Inhaled nebulised fentanyl for postoperative analgesia. *Anaesthesia.* 1991;46:973–6. [PubMed] [Google Scholar]

16. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: An updated review. *Int J Pharm Investig.* 2012;2:2–11. [PMC free article] [PubMed] [Google Scholar]

17. Ivy DD, Doran AK, Smith KJ, Mallory GB, Jr, Beghetti M, Barst, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. *J Am Coll Cardiol.* 2008;51(2):161–9. [PMC free article] [PubMed] [Google Scholar]

18. Siobal MS. Pulmonary vasodilators. *Respir Care.* 2007;52:885–99. [PubMed] [Google Scholar]

19. Fala L. Afrezza (Insulin Human) inhalation powder approved for the treatment of patients with type 1 or type 2 diabetes. *Am Health Drug Benefits.* 2015;8:40–3. [PMC free article] [PubMed] [Google Scholar]

20. Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. *Nat Rev Drug Discov.* 2007;6:67–74.